The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.
暂无分享,去创建一个
B. Escudier | Y. Loriot | K. Fizazi | C. Massard | A. Bossi | A. Chauchereau | M. Gross-goupil | M. di Palma | M. Di Palma | M. Gross‐Goupil
[1] R. Labianca,et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. , 2008, European urology.
[2] R de Crevoisier,et al. The postchemotherapy PSA surge syndrome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] W. Oh,et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel , 2008, Cancer.
[5] J. Pignon,et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. , 2007, The Lancet. Oncology.
[6] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[7] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[8] P. Babb,et al. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons , 2002, BJU international.